Rett syndrome (RTT) is a neurodevelopmental disorder characterized by cognitive regression, wild-type male siblings that served as negative controls. In positive control mice carrying a maternally inherited Ube3a deletion, Ube3a sense transcript and protein levels were drastically reduced. Our data contrast with two recent reports of substantially decreased Ube3a expression in brain tissues of MeCP2-deficient mice. We, therefore, challenge the conclusion that decreased UBE3A/Ube3a expression contributes to the pathophysiology of RTT.
INTRODUCTION
Rett Syndrome (RTT, OMIM 312750) is characterized by normal neonatal development up to age 7-18 months followed by rapid regression of brain functions including loss of purposeful hand movements, truncal ataxia and deceleration of brain growth (1, 2) . Heterozygosity for sporadic mutations or deletions in MECP2, located at Xq28 and subject to X inactivation, is observed in ~90% of females with classic RTT. Males with an inactivating MECP2 mutation have no functional MeCP2 protein and suffer from lack of postnatal development, respiratory insufficiency and early death (3, 4) and reviewed in (5).
MeCP2, methyl-CpG binding protein 2, binds to methyl-CpG dinucleotides adjacent to A/T sequences (6, 7) . CpG methylation at gene promoters is often associated with transcriptional silencing. In cell culture systems, MeCP2 binds to methylated promoter regions and represses transcription of BRCA1, CCNA1, MDR1, H19 and several other genes or genomic elements (8) (9) (10) (11) . Although MeCP2 can silence methylated alleles in cell culture, gene expression microarray studies have discovered very few significant changes in samples from RTT individuals or MeCP2-deficient mice (12) (13) (14) (15) (16) . Imprinted genes are attractive potential targets of MeCP2 modulation because their parent-of-origin specific expression patterns are maintained by differentially methylated regions (DMRs), not limited to promoters (17) . Initial studies of imprinting status in samples from RTT individuals, however, showed normal expression of imprinted genes (18) .
A potential candidate for MeCP2 modulation is the UBE3A locus that is controlled by complex imprinting mechanisms in brain. UBE3A encodes E6AP (human papillomavirus E6-associated protein) that was initially discovered as a protein required for the association of 4 human papillomavirus with p53. E6AP is a ubiquitin ligase and mediates the ubiquitin-dependent degradation of p53. Mutations or deletions of UBE3A affecting the maternally inherited allele cause Angelman syndrome (AS, OMIM 105830), a neurodevelopmental disorder. The phenotypic overlap between RTT and AS includes microcephaly, seizures, absence of speech, ataxia and mental retardation. Therefore, the hypothesis that the genes responsible for the two disorders could be mechanistically linked, is attractive. UBE3A is imprinted in brain, and MeCP2 may mediate imprinting by binding to methylated DNA and silencing transcription.
UBE3A is biallelically expressed in peripheral tissues, but in brain the maternal allele is predominantly expressed (19, 20) . As the UBE3A promoter lacks a DMR, suppression of the paternal allele is thought to be mediated by a brain-specific anti-sense transcript (Ube3a-AS) that acts in cis (21) (22) (23) (24) . A recent report showed that maternal expression of Ube3a-AS reduces maternal expression of sense Ube3a in cis (25) . If MeCP2 deficiency were to cause de-repressed Ube3a-AS transcription from the maternal allele, a reduction of Ube3a sense transcript would be expected. Indeed, Ube3a expression levels were reported to be decreased in RTT brains and MeCP2-deficient mouse models. Samaco et al. (26) found a modest reduction (1.5-fold) in Ube3a mRNA and protein in whole brain samples of 10 week old MeCP2-deficient mice with either one of two different mutant alleles (27, 28) . This reduction was not due to alteration in allele-specific expression, however, and Ube3a-AS expression was unchanged. They concluded, nevertheless, that MeCP2 deficiency causes reduced Ube3a expression, as well as reduced RNA and a greater than ten-fold decrease in the level of E6AP protein in brains of male MeCP2-deficient mice with the Mecp2 tm1.1Bird/Y mutation (28) . These drastic changes were associated with biallelic expression of the Ube3a-AS transcript. Previous cDNA microarray studies by four different groups, however, had failed to detect a significant difference in UBE3A/Ube3a expression in MeCP2-deficient mouse or RTT brain (12, (14) (15) (16) . But Makedonski et al (29) studied Ube3a expression in the whole brain of neonatal mice, unlike previous studies that focused on older mice. (32) . The low levels of Ube3a transcripts detected could be derived from glia cells where imprinting of this locus is not observed (24) . These results would predict that in mice with paternally-derived deletion, the Ube3a transcript level should be 85-90% of normal. Since the majority of these mice die during the neonatal period, however, we were unable to obtain age-matched (P21) controls. We studied a litter of 3 day-old mice and found no differences between paternal deletion and wildtype sibs in the level of Ube3a transcripts (data not shown). This result may indicate a lower number of glia cells in 3 day-old brain or may simply be due to the limit of the qRT-PCR assay in detecting such small changes. The initial control experiment with the maternal Ube3a deletion mice documents that our quantitative RNA assay is able to detect robust changes and is specific for Ube3a.
Ube3a transcript levels are not significantly different in the brain of neonatal wild-type and

MeCP2-deficient mice
To evaluate the expression of Ube3a in neonatal MeCP2-deficient mouse brain, we extracted RNA from whole brains of three different litters born to Mecp2 tm1.1Bird/+ females. The mice had been obtained from the Jackson lab on a C57Bl/6J background and had been backcrossed to C57Bl/6J mice in our lab for at least six generations. The mothers were 2-4 mo old and asymptomatic. The litters included six wild-type, three heterozygotes, and five male mutants.
We performed qRT-PCR with SYBR Green and analyzed the data using the Standard Curve
Method (Applied Biosystems) to determine the relative amount of Ube3a mRNA compared to endogenous controls. Mecp2 expression was also evaluated in all samples and correlated with the genotype (Figure 2A ).
We found no significant difference in Ube3a expression in the whole brain of neonatal
Mecp2-mutant and wild-type mice ( Figure 2A ). The standard error of mean (SEM) is overlapping for each set of samples, and unpaired t-tests revealed P > 0.4. These data differ from the six-fold decrease in Ube3a expression reported by Makedonski et al (29) . Attempting to reproduce their published data, we used mice with the same mutant allele (Mecp2 tm1.1Bird/y ) on the same C57Bl/6J background and at the same age (1-3 days). In comparison, Samaco et al (26) reported qRT-PCR data for only two sets of male "Mecp2-null" mice and normal littermates at 10 weeks of age, with the allele not specified. Although Ube3a expression in whole brain was lower in the mutants, the SEM data, based on four experimental repetitions, show a wide range, and the results are not statistically significant.
Having confirmed that neurons in the cerebellum preferentially express Ube3a from the maternal allele (Figure 1 ), we then compared the expression of Ube3a in the cerebellum of
Mecp2-mutant and wild-type mice at eight weeks of age. We compared two different Mecp2-mutant alleles. Mecp2 tm1.1Jae/Y (J-allele) has an in-frame deletion of exon 3 and produces a stable mRNA (27) . Exon 3 encodes part of the methyl-CpG binding domain (MBD) of MeCP2.
Mecp2
tm1.1Bird/Y (B allele) is deleted for exon 3 and the coding region of exon 4; it does not produce a stable mRNA (28) . Six mutant and six wild-type males with the J allele and eight mutant and six wild-type males with the B allele were tested. We found no significant differences in the level of Ube3a transcripts between mutant and wild-type mice of either allele ( Figure 2B ). Real-time qRT-PCR reliably detects changes in expression that are at least two-fold (33) (Ambion Technical Bulletin). We, therefore, conclude that Ube3a expression is changed by less than two-fold, if at all, in MeCP2-deficient mice. As Mecp2 tm1.1Bird/Y mice were on a C57Bl/6J background and Mecp2 tm1.1Jae/Y mice on a 129/Sv, C57BL/6 and BALB/c mixed background, we conclude that strain background is not a major contributor to the reported Ube3a expression differences.
E6AP levels are similar in the brain of wild-type and Mecp2-mutant mice
We next took the analysis to the protein level by studying E6AP, the ~100 kDa protein product encoded by the Ube3a gene. In situ hybridization studies of mice with partial uniparental disomy for chromosome 7 had shown that Ube3a is exclusively expressed from the maternal allele in hippocampal neurons and Purkinje cells (34) . To confirm the specificity of our antibody, we analyzed immunoblots with samples from a mouse with a maternal deletion of Ube3a ( 
DISCUSSION
To determine whether Ube3a is an in vivo target of MeCP2, possibly via relaxation of Ube3a-AS
imprinting in neurons, we evaluated Ube3a expression in whole brain and cerebellum of MeCP2-deficient mice using qRT-PCR and Western blot analysis. Neonatal or eight week old mice from 15 different litters and from two different Mecp2-mutant mouse models were examined. No significant change in Ube3a expression was observed. We first optimized our qRT-PCR and Western blot assays by using both negative and positive controls. qRT-PCR is a very robust procedure that reliably distinguishes two-fold differences between two RNA samples. Our results differ markedly from the six-fold decrease in RNA levels and ten-fold decrease in protein levels reported by Makedonski et al (29) . 
Materials and Methods
MeCP2-deficient mice. Female heterozygotes for a Mecp2 mutation (B allele) (Mecp2 tm1.1Bird ) (28) were purchased from The Jackson Laboratory where they had been bred on C57BL/6J for several generations. At Stanford, heterozygous females were bred for at least 6 generations to C57BL/6J males. For the studies reported here, the females were 2-4 months old at the time of delivery and asymptomatic. Newborn mice were genotyped for Mecp2 and Sry (for sexing).
Primers are available on request. Mecp2 tm1.1Jae (J allele) (27) heterozygotes were obtained from Dr. Rudolf Jaenisch on a mixed 129/Sv, C57Bl/6 and BALB/c background and were bred for several generations to BALB/cJ males. ( Western blot analysis. Whole brain samples were rapidly homogenized in lysis buffer with a mortar and pestle and then boiled for 3-5 min in lysis buffer (10mM Tris pH 7.4, 1% SDS).
Snrpn-Ube3a deletion mice
Protein samples were quantitated using a modified Lowry assay (Bio-Rad DC Protein Assay).
Quantities ranging from 2.5 µg to 10µg were separated by polyacrylamide gel electrophoresis and transferred to PVDF membranes. A monoclonal mouse antibody against E6AP amino acids 501 to 712 (BD Transduction Laboratories, Cat. # 611416) was used, at 1:500 and 1:1000 dilutions in blocking buffer, followed by an HRP-conjugated secondary antibody at 1:1000 in blocking buffer. The procedures were optimized with control mice having a Ube3a deletion (31). B. Ube3a expression in cerebellum of 8-wk old mice that are null for Mecp2 (B allele) or harbor an in-frame deletion of exon 3 Mecp2 tm1.1Jae/y (J allele). The B allele samples were derived from six wild-type and eight mutant mice from five different litters; and the J allele samples were from six mutant and six wild-type males of four different litters. The cDNA-derived amplicon spans two exons that are separated by a 7.7kb intron. All samples were run in triplicate, and each experiment was performed at least twice. Mouse β2-microglobulin was amplified as control.
Error bars represent SEM. There is no significant difference in Ube3a transcript levels between
Mecp2 mutant and wild-type males (two-tailed t-test, P= 0.77). 
